Sofgen Pharma S.A. (PROCF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSofgen Pharma S.A. (PROCF) trades at $0.0001. Procaps Group S.A. is a global pharmaceutical company specializing in the development and commercialization of a diverse range of medical solutions. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for PROCF: PROCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Sofgen Pharma S.A. (PROCF) Healthcare & Pipeline Overview
Procaps Group S.A. (PROCF) excels in the pharmaceutical sector with a comprehensive portfolio of prescription drugs and OTC products, addressing multiple therapeutic areas and providing contract drug development services, positioning itself as a versatile player in the global healthcare market.
What Is the Investment Thesis for PROCF?
The company boasts a profit margin of 10.4% and a gross margin of 58.4%, indicating operational efficiency. Key growth catalysts include the expansion of its OTC product range and increasing demand for diabetes management solutions, projected to grow significantly in the coming years. Furthermore, Procaps' specialization as a CDMO provider positions it favorably against competitors, allowing for additional revenue streams. However, risks such as regulatory challenges and market competition must be carefully monitored. With a P/E ratio of 0.00, the company appears undervalued compared to industry peers, suggesting potential for future appreciation.
Based on FMP financials and quantitative analysis
PROCF Key Highlights
Market Cap of $0.06B reflects a niche position in the pharmaceutical market.
- P/E ratio of 0.00 indicates potential undervaluation compared to industry standards.
- Profit margin of 10.4% demonstrates effective cost management and operational efficiency.
- Gross margin of 58.4% exceeds industry averages, highlighting strong pricing power.
- Beta of 8.49 suggests high volatility, indicating potential risks in market fluctuations.
Who Are PROCF's Competitors?
PROCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| PFE Pfizer Inc. | $27.80 | -1.14% | $158B | 68 5-pillar |
| JNJ Johnson & Johnson | $256.03 | -1.02% | $617B | 90 5-pillar |
| MRK Merck & Co., Inc. | $144.30 | +0.34% | $356B | 75 5-pillar |
| ABBV AbbVie Inc. | $262.82 | +1.11% | $464B | 78 5-pillar |
| BMY Bristol-Myers Squibb Company | $61.15 | -0.50% | $125B | 91 5-pillar |
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROCF's Key Strengths?
Diverse product portfolio covering various therapeutic areas.
- Strong operational efficiency with high gross and profit margins.
- Established presence in both prescription and OTC markets.
- Expertise in soft gelatin capsule technologies enhances product offerings.
What Are PROCF's Weaknesses?
Limited brand recognition compared to larger pharmaceutical companies.
- Dependence on a few key therapeutic areas for revenue generation.
- Exposure to regulatory risks in the pharmaceutical industry.
- No dividend yield may deter income-focused investors.
What Are the Key Risks for PROCF?
Financial-distress signal — its Altman Z-Score of 0.04 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 6 reported quarters.
- Regulatory challenges could delay product approvals and market entry.
- Intense competition from larger pharmaceutical companies may impact market share.
- Market volatility affecting stock performance and investor sentiment.
- Risks associated with patent expirations and the emergence of generic competitors.
What Are PROCF's Competitive Advantages?
- Strong brand recognition in various therapeutic areas enhances customer loyalty.
- Specialization in soft gelatin capsule technologies provides a competitive edge in product formulation.
- Established relationships with healthcare providers and institutions support consistent revenue streams.
- Diverse product portfolio mitigates risks associated with market fluctuations in specific segments.
What Does PROCF Do?
Procaps Group S.A., founded in 1977 and headquartered in Luxembourg City, is a prominent global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company has evolved significantly over the decades, establishing a strong presence in various therapeutic areas including women's health, pain relief, dermatological conditions, and more. Procaps offers a robust portfolio that includes branded prescription drugs and a wide array of over-the-counter (OTC) products spanning approximately eight therapeutic categories such as gastrointestinal health, skincare, cough and cold remedies, and pain management. Additionally, the company supplies pharmaceutical products for hospital use, including antibiotics, anticoagulants, and oncology treatments, showcasing its commitment to addressing critical healthcare needs. Procaps also provides comprehensive diabetes management solutions, which include blood glucose monitors and insulin delivery systems. As a contract drug development and manufacturing (CDMO) provider, Procaps specializes in soft gelatin capsule technologies, enhancing its competitive positioning in the pharmaceutical landscape. With a workforce of around 5,000 employees, Procaps continues to expand its market reach and innovate within the healthcare sector.
What Products and Services Does PROCF Offer?
- Develops and manufactures a diverse range of prescription drugs across various therapeutic areas.
- Offers a wide selection of over-the-counter (OTC) healthcare products.
- Provides pharmaceutical products for hospital use, including antibiotics and oncology treatments.
- Specializes in diabetes management solutions, including blood glucose monitors and insulin delivery systems.
- Operates as a contract drug development and manufacturing (CDMO) provider for other pharmaceutical companies.
- Utilizes advanced soft gelatin capsule technologies in its product offerings.
How Does PROCF Make Money?
- Generates revenue through the sale of prescription and OTC pharmaceutical products.
- Provides contract drug development services to other pharmaceutical companies.
- Offers specialized diabetes management solutions, contributing to diversified income streams.
- Engages in R&D to innovate and develop new therapeutic products.
- Utilizes its expertise in soft gelatin capsule technologies to enhance product offerings.
What Industry Does PROCF Operate In?
The pharmaceutical industry, particularly the specialty and generic drug manufacturing sector, is experiencing robust growth, driven by increasing healthcare demands and an aging population. Procaps Group S.A. is well-positioned within this landscape, leveraging its diverse product offerings and expertise in various therapeutic areas to compete effectively against established players. The competitive landscape includes both large multinational corporations and specialized firms, making innovation and regulatory compliance critical for success.
Who Are PROCF's Key Customers?
- Healthcare providers and hospitals seeking pharmaceutical products.
- Consumers purchasing over-the-counter healthcare solutions.
- Pharmaceutical companies requiring contract development and manufacturing services.
- Patients managing chronic conditions, particularly diabetes.
- Retail pharmacies and distributors for OTC product sales.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Sofgen Pharma S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Luxembourg.
Key Financial Metrics
Return on assets is 8.5%, showing how much profit it generates from its asset base. PROCF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.10x. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Sofgen Pharma S.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.04 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Sofgen Pharma S.A. has missed Wall Street's EPS estimate in 3 of its last 6 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 37.1% below estimates on average.
PROCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PROCF Latest News
No recent news available for PROCF.
PROCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PROCF.
Price Targets
Wall Street price target analysis for PROCF.
PROCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PROCF; grades run from A+ (80-100) to F (below 30).
Leadership: Melissa Angelini
CEO
Melissa Angelini has a robust background in the pharmaceutical industry, with over 20 years of experience in various leadership roles. She holds a degree in Pharmacy and an MBA, equipping her with both technical and business acumen. Prior to her role at Procaps, she held significant positions at leading pharmaceutical firms, driving growth and innovation.
Track Record: Under Melissa's leadership, Procaps has expanded its product offerings and enhanced its market presence, focusing on innovation and operational efficiency. She has been instrumental in navigating regulatory challenges and fostering strategic partnerships.
PROCF OTC Market Information
The OTC Other tier represents stocks that trade over-the-counter but do not meet the requirements for the more regulated exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements, leading to potential information asymmetry for investors.
- OTC Tier: OTC Other
- Limited regulatory oversight may increase the risk of fraud or mismanagement.
- Lower trading volumes can lead to higher volatility and price fluctuations.
- Potential lack of transparency in financial reporting and disclosures.
- Increased susceptibility to market manipulation due to lower liquidity.
- Verify the company's financial health through available reports.
- Assess the management team's track record and experience.
- Examine the competitive landscape and market positioning.
- Monitor regulatory developments affecting the pharmaceutical sector.
- Review product pipeline and upcoming clinical trials.
- Established history since 1977 indicates a long-term presence in the industry.
- Diverse product portfolio across multiple therapeutic areas.
- Recognition as a CDMO provider showcases industry credibility.
- Engagement in R&D activities demonstrates commitment to innovation.
PROCF Healthcare Stock FAQ
What do analysts say about PROCF stock?
Analysts generally view Procaps Group S.A. as a company with potential for growth due to its diverse product offerings and strong market position.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information and may be subject to change.